ATCvet code:
QD11AH92
Pharmacodynamics
Ilunocitinib is a Janus kinase (JAK) inhibitor. It inhibits the function of a variety of pruritogenic and pro-inflammatory cytokines, as well as cytokines involved in allergy which are dependent on JAK enzyme activity. Ilunocitinib has minimal impact on other protein and lipid kinases and has therefore limited risk of off-target effects. Ilunocitinib may also exert effects on other cytokines (for example, those involved in immune defense or haematopoiesis), which may have the potential for unwanted effects.
Pharmacokinetics
Ilunocitinib is rapidly and well absorbed after oral administration in dogs. After oral administration of the tablet at 0.8 mg/kg ilunocitinib in fed dogs, the absolute bioavailability was 80 %. The elimination half-life was 5.0 hours. In fasted dogs, oral bioavailability was 58 % showing a similar elimination half-life as observed in fed dogs (5.4 hours). Time to peak plasma concentrations (tmax) was between 1 to 4 hours.
After repeated oral administration there was no significant accumulation.
The route of elimination of ilunocitinib is balanced between the faecal and urinary routes.
After intravenous administration of 0.8 mg/kg, ilunocitinib had a low plasma clearance of 437 mL/h/kg. The volume of distribution was 1.58 L/kg and terminal half-life was 4.4 hours.